Functional Genomics for Hormone Health: How Your DNA Shapes Perimenopause, HRT, and Medication Response
Medically reviewed by Dr. Mia Chorney, DNP, FNP-BC, MSCP — Cofounder & Chief Medical Officer, Amsara Health
Two women start the same dose of the same antidepressant for perimenopausal mood changes. One feels better in three weeks. The other feels nothing, or feels worse, and concludes that medication does not work for her. Very often the difference is not willpower or bad luck. It is a gene, usually one that governs how quickly her liver clears the drug. Functional genomics is the discipline of reading those genes before the prescription is written. Here is what it can do for midlife hormone and metabolic care, what it cannot, and how to tell the difference between the two.
What is functional genomics, and how is it different from 23andMe?
The term covers two overlapping ideas. Pharmacogenomics, often shortened to PGx, examines how inherited variation affects the way your body absorbs, activates, and clears medications. Nutrigenomics examines how genes interact with nutrients, from folate metabolism to caffeine clearance. Neither diagnoses disease. Both are about response: how your particular biology is likely to handle a particular input.
An ancestry-style consumer test is a different product. 23andMe’s pharmacogenetic reports cover a handful of variants in two genes and carry the instruction not to use the results to start, stop, or change any treatment without confirmatory clinical testing. A clinical-grade functional genomics panel run through a CLIA-certified laboratory covers the full set of well-characterized drug-metabolizing genes and is designed to be acted on by a prescriber. And both differ from a diagnostic genetic test such as BRCA1/2, which asks a yes-or-no question about disease risk. The American College of Medical Genetics has been clear for a decade that genomic results of any kind belong in the hands of a clinician who can interpret them in context. We agree, which is why every panel at Amsara is reviewed with you by your provider.
Which gene-drug pairs have strong evidence?
The Clinical Pharmacogenetics Implementation Consortium (CPIC) grades gene-drug pairs and writes prescribing guidelines only for the best-supported ones. Several sit squarely in midlife care:
- CYP2C19 and common antidepressants. Poor metabolizers of citalopram and escitalopram accumulate the drug; CPIC’s 2023 guideline recommends a lower starting dose and a maintenance dose about half the usual, and the FDA caps citalopram at 20 mg per day in this group because of heart-rhythm risk. Ultrarapid metabolizers may clear the drug so fast that a standard dose never reaches a working level, which is one explanation for the “it did nothing” experience.
- SLCO1B1 and statins. People with reduced transporter function face a higher risk of muscle pain on simvastatin. CPIC recommends avoiding simvastatin altogether and capping atorvastatin and rosuvastatin doses, which is directly relevant when cardiovascular prevention enters the conversation after menopause.
- CYP2D6 and tamoxifen. For women taking tamoxifen after breast cancer, poor metabolizers convert less of the drug into its active form. CPIC recommends an aromatase inhibitor instead where appropriate. The FDA lists this pair at a lower evidence tier, so it is a conversation with your oncologist, not a unilateral change.
- CYP2C9, VKORC1, and warfarin. Genotype-guided dosing algorithms are written into the warfarin label itself.
- Factor V Leiden and estrogen. This is the pair most relevant to hormone therapy. Women who carry the Factor V Leiden variant have a substantially higher risk of blood clots on oral estrogen; GeneReviews cites odds roughly sixteen-fold higher on oral hormone therapy compared with under five-fold on transdermal. Knowing carrier status changes the route, the dose, and sometimes the decision.
The FDA’s Table of Pharmacogenetic Associations now lists well over a hundred drugs with recognized gene interactions, and a 2026 review estimates that up to 60 percent of primary care patients take at least one medication with a known gene-drug interaction.
Does testing actually change outcomes?
Yes, measurably. The PREPARE trial, published in The Lancet in 2023, randomized 6,944 patients across seven European countries to genotype-guided prescribing using a twelve-gene panel or usual care. Clinically relevant adverse drug reactions fell from 27.7 percent to 21.0 percent, a 30 percent relative reduction, and 93.5 percent of participants carried at least one actionable variant. Mayo Clinic puts the figure similarly: more than nine in ten people carry a clinically significant variant. The odds that a panel finds nothing relevant to you are low.
What about genes for estrogen metabolism, COMT, and MTHFR?
This is where honest practices part ways with marketing. Several enzymes involved in estrogen metabolism, including CYP3A4, CYP1A2, and COMT, have common variants, and it is plausible that they influence how a woman handles hormone therapy. Plausible is not proven. There is no CPIC guideline and no FDA labeling for any of them, and the supporting studies are small and inconsistent. At Amsara we treat these results as one input into a clinical judgment about dose and route, alongside your symptoms and your labs, never as a rule that sets your prescription.
MTHFR deserves its own sentence because it is the most over-interpreted gene in consumer wellness. The American College of Medical Genetics states that MTHFR testing has minimal clinical utility and should not be ordered to evaluate clotting risk or recurrent pregnancy loss. A common MTHFR variant with a normal homocysteine level is a normal finding. If your panel reports one, your provider will tell you exactly that.
What does a functional genomics panel involve at Amsara?
A cheek swab collected at home and returned to a CLIA-certified laboratory, with results in a few weeks. Our Functional Genomics Essential panel includes a pharmacogenomic report and a year of portal access, so the findings stay attached to your record and can be checked every time a new medication is considered. The Complete panel adds a broader library of reports across cardiac, cognitive, inflammatory, and detoxification pathways. Both are ordered by your provider and walked through with you at a follow-up visit; neither is sold as a standalone product, because a genomic report without a clinician attached is exactly what the ACMG warns against.
Two limitations you should know. First, these panels use SNP arrays, which read common variants very well but can miss rare variants and structural changes; a specific clinical question sometimes calls for sequencing instead. Second, genes are a fixed input in a system full of moving parts. Diet, sleep, muscle mass, alcohol, and the other medications you take frequently matter more than a single variant, which is why the report is read with your labs and your life, not instead of them.
Why does this matter more in perimenopause?
Because midlife is when prescriptions multiply. A woman in her late forties may be weighing hormone therapy, an antidepressant, a statin, a sleep aid, and a GLP-1 medication within the same two years, often from different prescribers. Knowing in advance which of those her body will clear slowly, and which route of estrogen carries the least clot risk for her, turns a sequence of trial and error into a plan. It is the same logic behind everything in our care for women: measure first, then decide. If you are already a patient, you can ask your provider to add the panel through your portal. If you are not, it begins with a single initial visit.
Frequently asked questions
Is functional genomics testing the same as 23andMe?
No. Consumer ancestry tests report a small number of variants and warn against using them to change treatment. A clinical functional genomics panel is run in a CLIA-certified lab, covers the full set of well-studied drug-metabolizing genes, and is interpreted by a prescriber.
Can a genomic test tell me whether hormone therapy is safe for me?
Partly. Carrier status for Factor V Leiden and related clotting variants meaningfully changes clot risk on oral estrogen and favors transdermal routes. Genes involved in estrogen metabolism, such as COMT and CYP3A4, are not yet supported by clinical guidelines and are used only as supporting information.
I have an MTHFR variant. Do I need special hormones or supplements?
Usually not. The American College of Medical Genetics states that MTHFR testing has minimal clinical utility. A common variant with a normal homocysteine level is a normal finding. Your provider will review your actual labs rather than the variant alone.
Will my results change how my doctor prescribes antidepressants or statins?
They can. CPIC guidelines recommend dose changes or alternative drugs for CYP2C19 variants with citalopram, escitalopram, and sertraline, and for SLCO1B1 variants with simvastatin and other statins.
How is the sample collected, and how long do results take?
A cheek swab collected at home and mailed to the laboratory. Results typically return within a few weeks and are reviewed with you at a follow-up telehealth visit.
Do I need to repeat a functional genomics test?
No. Your inherited variants do not change. The interpretation can, as guidelines evolve, which is why Amsara keeps the report attached to your record with a year of portal access for reference whenever a new medication is considered.
Does a ‘poor metabolizer’ result mean a medication will not work for me?
Not necessarily. It usually means the drug will build up more than average, so a lower dose or a different drug in the same class may be safer. Ultrarapid metabolizers have the opposite problem and may need a different medication entirely.
Is functional genomics testing available by telehealth in Arizona?
Yes. Amsara Health orders the panel for Arizona patients, the swab is collected at home, and results are reviewed at a video visit with your provider.
This article is for education only and is not medical advice. Talk with a qualified clinician about your individual health before starting or stopping any therapy.
Want your care built on your biology?
Unhurried appointments, advanced diagnostics, and a plan built for you.
Already a patient? Visit your Amsara Patient Portal →
